Skip to main content
SpringerLink
Log in
Book cover

Pediatric Obesity pp 47–64Cite as

Syndromic Obesity

  • Chapter
  • First Online:

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

It is well established that genetic mutations or chromosomal abnormalities can lead to obesity. The term “syndromic obesity” is used to describe obese children and adults with mental retardation, dysmorphic features, organ-specific abnormalities, hyperphagia, and/or other signs of hypothalamic dysfunction (1, 2.) Obesity syndromes may be inherited in either an autosomal or an X-linked pattern.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet. 2005;6(3):221–34.

    Article  PubMed  CAS  Google Scholar 

  2. Farooqi IS, O’Rahilly S. Monogenic obesity in humans. Annu Rev Med. 2005;56:443–58.

    Article  PubMed  CAS  Google Scholar 

  3. Prader A, Labhart A, Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach myotoniertigem Zustand im Neugeborenalter. Schweiz Med Wochenschr. 1956;86:1260–1.

    Google Scholar 

  4. Cassidy SB, Dykens E, Williams CA. Prader-Willi and Angelman syndromes: sister imprinted disorders. Am J Med Genet. 2000;97(2):136–46.

    Article  PubMed  CAS  Google Scholar 

  5. de Lind van Wijngaarden RF, Otten BJ, Festen DA, Joosten KF, de Jong FH, Sweep FC, Hokken-Koelega AC. High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93(5):1649–54.

    Article  PubMed  CAS  Google Scholar 

  6. DiMario FJ Jr, Dunham B, Burleson JA, Moskovitz J, Cassidy SB. An evaluation of autonomic nervous system function in patients with Prader-Willi syndrome. Pediatrics. 1994;93(1):76–81.

    PubMed  Google Scholar 

  7. Nicholls RD, Knepper JL. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu Rev Genomics Hum Genet. 2001;2:153–75.

    Article  PubMed  CAS  Google Scholar 

  8. Nicholls RD, Saitoh S, Horsthemke B. Imprinting in Prader-Willi and Angelman syndromes. Trends Genet. 1998;14(5):194–200.

    Article  PubMed  CAS  Google Scholar 

  9. Ohta T, Gray TA, Rogan PK, Buiting K, Gabriel JM, Saitoh S, Muralidhar B, Bilienska B, Krajewska-Walasek M, Driscoll DJ, Horsthemke B, Butler MG, Nicholls RD. Imprinting-mutation mechanisms in Prader-Willi syndrome. Am J Hum Genet. 1999;64(2):397–413.

    Article  PubMed  CAS  Google Scholar 

  10. Runte M, Huttenhofer A, Gross S, Kiefmann M, Horsthemke B, Buiting K. The IC-SNURF-SNRPN transcript serves as a host for multiple small nucleolar RNA species and as an antisense RNA for UBE3A. Hum Mol Genet. 2001;10(23):2687–700.

    Article  PubMed  CAS  Google Scholar 

  11. Niinobe M, Koyama K, Yoshikawa K. Cellular and subcellular localization of necdin in fetal and adult mouse brain. Dev Neurosci. 2000;22(4):310–19.

    Article  PubMed  CAS  Google Scholar 

  12. Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, Le Moal M, Cau P, Cremer H. Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum Mol Genet. 2000;9(20):3101–10.

    Article  PubMed  CAS  Google Scholar 

  13. Lee S, Kozlov S, Hernandez L, Chamberlain SJ, Brannan CI, Stewart CL, Wevrick R. Expression and imprinting of MAGEL2 suggest a role in Prader-Willi syndrome and the homologous murine imprinting phenotype. Hum Mol Genet. 2000;9(12):1813–19.

    Article  PubMed  CAS  Google Scholar 

  14. Gallagher RC, Pils B, Albalwi M, Francke U. Evidence for the role of PWCR1/HBII-85 C/D box small nucleolar RNAs in Prader-Willi syndrome. Am J Hum Genet. 2002;71(3):669–78.

    Article  PubMed  CAS  Google Scholar 

  15. Festen DA, Wevers M, Lindgren AC, Bohm B, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC. Mental and motor development before and during growth hormone treatment in infants and toddlers with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2008;68(6):919–25.

    Article  CAS  Google Scholar 

  16. Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Clin Endocrinol (Oxf). 2008;69(3):443–51.

    Article  CAS  Google Scholar 

  17. Myers SE, Whitman BY, Carrel AL, Moerchen V, Bekx MT, Allen DB. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A. 2007;143(5): 443–48.

    PubMed  Google Scholar 

  18. Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab. 2002;87(4):1581–85.

    Article  PubMed  CAS  Google Scholar 

  19. Carrel AL, Myers SE, Whitman BY, Allen DB. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr. 1999;134(2):215–21.

    Article  PubMed  CAS  Google Scholar 

  20. Eiholzer U, l’Allemand D. Growth hormone normalises height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy. Horm Res. 2000;53(4):185–92.

    Article  PubMed  CAS  Google Scholar 

  21. Myers SE, Carrel AL, Whitman BY, Allen DB. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr. 2000;137(1):42–49.

    Article  PubMed  CAS  Google Scholar 

  22. Carrel AL, Myers SE, Whitman BY, Allen DB. Sustained benefits of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome are dose-dependent. J Pediatr Endocrinol Metab. 2001;14(8):1097–105.

    PubMed  CAS  Google Scholar 

  23. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(5):2206–12.

    Article  PubMed  CAS  Google Scholar 

  24. Bakker B, Maneatis T, Lippe B. Sudden death in Prader-Willi syndrome: brief review of five additional cases. Concerning the article by U. Eiholzer et al.: Deaths in children with Prader-Willi syndrome. A contribution to the debate about the safety of growth hormone treatment in children with PWS (Horm Res 2005;63:33–39). Horm Res. 2007;67(4):203–4.

    Article  PubMed  CAS  Google Scholar 

  25. Tauber M, Diene G, Molinas C, Hebert M. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A. 2008;146(7):881–87.

    PubMed  CAS  Google Scholar 

  26. Schrander-Stumpel CT, Curfs LM, Sastrowijoto P, Cassidy SB, Schrander JJ, Fryns JP. Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet A. 2004;124(4):333–38.

    Article  Google Scholar 

  27. Vogels A, Van Den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E, Fryns JP. Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet. 2004;12(3):238–40.

    Article  PubMed  CAS  Google Scholar 

  28. Van Vliet G, Deal CL, Crock PA, Robitaille Y, Oligny LL. Sudden death in growth hormone-treated children with Prader-Willi syndrome. J Pediatr. 2004;144(1):129–31.

    Article  PubMed  Google Scholar 

  29. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS. Elevated plasma ghrelin levels in Prader-Willi syndrome. Nat Med. 2002;8(7):643–644.

    Article  PubMed  CAS  Google Scholar 

  30. DelParigi A, Tschop M, Heiman ML, Salbe AD, Vozarova B, Sell SM, Bunt JC, Tataranni PA. High Circulating Ghrelin: A Potential Cause for Hyperphagia and Obesity in Prader-Willi Syndrome. J Clin Endocrinol Metab. 2002;87(12): 5461–64.

    Article  PubMed  CAS  Google Scholar 

  31. Haqq AM, Farooqi IS, O’Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL, LaFranchi SH, Purnell JQ. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(1):174–78.

    Article  PubMed  CAS  Google Scholar 

  32. Haqq AM, Grambow SC, Muehlbauer M, Newgard CB, Svetkey LP, Carrel AL, Yanovski JA, Purnell JQ, Freemark M. Ghrelin concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development. Clin Endocrinol (Oxf). 2008;69(6):911–20.

    Article  CAS  Google Scholar 

  33. Haqq AM, Stadler DD, Rosenfeld RG, Pratt KL, Weigle DS, Frayo RS, LaFranchi SH, Cummings DE, Purnell JQ. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2003;88(8):3573–76.

    Article  PubMed  CAS  Google Scholar 

  34. Tan TM, Vanderpump M, Khoo B, Patterson M, Ghatei MA, Goldstone AP. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2004;89(8):4162–65.

    Article  PubMed  CAS  Google Scholar 

  35. De Waele K, Ishkanian SL, Bogarin R, Miranda CA, Ghatei MA, Bloom SR, Pacaud D, Chanoine JP. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. Eur J Endocrinol. 2008;159(4):381–88.

    Article  PubMed  CAS  Google Scholar 

  36. Goldstone AP, Thomas EL, Brynes AE, Bell JD, Frost G, Saeed N, Hajnal JV, Howard JK, Holland A, Bloom SR. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab. 2001;86(9):4330–38.

    Article  PubMed  CAS  Google Scholar 

  37. Goldstone AP, Brynes AE, Thomas EL, Bell JD, Frost G, Holland A, Ghatei MA, Bloom SR. Resting metabolic rate, plasma leptin concentrations, leptin receptor expression, and adipose tissue measured by whole-body magnetic resonance imaging in women with Prader-Willi syndrome. Am J Clin Nutr. 2002;75(3):468–75.

    PubMed  CAS  Google Scholar 

  38. Haqq AM, Muehlbauer M, Svetkey LP, Newgard CB, Purnell JQ, Grambow SC, Freemark MS. Altered distribution of adiponectin isoforms in children with Prader-Willi syndrome (PWS): association with insulin sensitivity and circulating satiety peptide hormones. Clin Endocrinol (Oxf). 2007;67(6):944–51.

    Article  CAS  Google Scholar 

  39. Wade CK, De Meersman RE, Angulo M, Lieberman JS, Downey JA. Prader-Willi syndrome fails to alter cardiac autonomic modulation. Clin Auton Res. 2000;10(4):203–6.

    Article  PubMed  CAS  Google Scholar 

  40. Albright F, Burnett C, Smith P, Parson W. Pseudohypoparathyroidism: an example of Seabright-Bantam syndrome. Endocrinology. 1942;30:922–32.

    CAS  Google Scholar 

  41. Levine MA, Germain-Lee E, Jan de Beur S. Genetic basis for resistance to parathyroid hormone. Horm Res. 2003;60: 87–95. See also Germain-Lee EL. Short stature, obesity, and growth hormone deficiency in pseudohypoparathyroidism type 1a. Pediatr Endocrinol Rev 2006;3(Suppl 2):318–27.

    Article  PubMed  CAS  Google Scholar 

  42. Albright F, Forbes A, Henneman P. Pseudopseudohypoparathyroidism. Trans Assoc Am Physicians. 1952;65:337–50.

    PubMed  CAS  Google Scholar 

  43. Ong KK, Amin R, Dunger DB. Pseudohypoparathyroidism – another monogenic obesity syndrome. Clin Endocrinol (Oxf). 2000;52(3):389–91.

    Article  CAS  Google Scholar 

  44. Miric A, Vechio JD, Levine MA. Heterogeneous mutations in the gene encoding the alpha-subunit of the stimulatory G protein of adenylyl cyclase in Albright hereditary osteodystrophy. J Clin Endocrinol Metab. 1993;76(6): 1560–68.

    Article  PubMed  CAS  Google Scholar 

  45. Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. Minireview: GNAS: Normal and Abnormal Functions. Endocrinology. 2004;145(12):5459–64.

    Article  PubMed  CAS  Google Scholar 

  46. Nakamoto JM, Sandstrom AT, Brickman AS, Christenson RA, Van Dop C. Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation. Am J Med Genet. 1998;77(4):261–67.

    Article  PubMed  CAS  Google Scholar 

  47. Davies SJ, Hughes HE. Imprinting in Albright’s hereditary osteodystrophy. J Med Genet. 1993;30(2):101–3.

    Article  PubMed  CAS  Google Scholar 

  48. Laurence JZ, Moon RC. Four cases of retinitis pigmentosa occurring in the same family, and accompanied by general imperfections of development. Ophthalmol Rev. 1866;2:32–41.

    Google Scholar 

  49. Bardet G. Sur un syndrome d’obesite congenitale avec plydactylie et retinite pigmentaire (contribution a l’etude des formes cliniques de l’obesite hypophysaire). These de Paris (Le Grand). 1920;470:107.

    Google Scholar 

  50. Biedl A. Ein Geschwister mit adiposogenitaler Dystrophie. Dtsch Med Wochenschr. 1922;48:1630.

    Google Scholar 

  51. Beales PL, Warner AM, Hitman GA, Thakker R, Flinter FA. Bardet-Biedl syndrome: a molecular and phenotypic study of 18 families. J Med Genet. 1997;34(2):92–98.

    Article  PubMed  CAS  Google Scholar 

  52. Klein D, Ammann F. The syndrome of Laurence-Moon-Bardet-Biedl and allied diseases in Switzerland: Clinical, genetic and epidemiological studies. J Neurol Sci. 1969;9(3):479–513.

    Article  PubMed  CAS  Google Scholar 

  53. Farag TI, Teebi AS. High incidence of Bardet Biedl syndrome among the Bedouin. Clin Genet. 1989;36(6):463–4.

    Article  PubMed  CAS  Google Scholar 

  54. Green JS, Parfrey PS, Harnett JD, Farid NR, Cramer BC, Johnson G, Heath O, McManamon PJ, O’Leary E, Pryse-Phillips W. The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. N Engl J Med. 1989;321(15):1002–9.

    Article  PubMed  CAS  Google Scholar 

  55. Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437–46.

    PubMed  CAS  Google Scholar 

  56. Grace C, Beales P, Summerbell C, Jebb SA, Wright A, Parker D, Kopelman P. Energy metabolism in Bardet-Biedl syndrome. Int J Obes Relat Metab Disord. 2003;27(11):1319–24.

    Article  PubMed  CAS  Google Scholar 

  57. Ansley SJ, Badano JL, Blacque OE, Hill J, Hoskins BE, Leitch CC, Chul Kim J, Ross AJ, Eichers ER, Teslovich TM, Mah AK, Johnsen RC, Cavender JC, Alan Lewis R, Leroux MR, Beales PL, Katsanis N. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature. 2003;425(6958):628–33.

    Article  PubMed  CAS  Google Scholar 

  58. Kulaga HM, Leitch CC, Eichers ER, Badano JL, Lesemann A, Hoskins BE, Lupski JR, Beales PL, Reed RR, Katsanis N. Loss of BBS proteins causes anosmia in humans and defects in olfactory cilia structure and function in the mouse. Nat Genet. 2004;36(9):994–98.

    Article  PubMed  CAS  Google Scholar 

  59. Nishimura DY, Fath M, Mullins RF, Searby C, Andrews M, Davis R, Andorf JL, Mykytyn K, Swiderski RE, Yang B, Carmi R, Stone EM, Sheffield VC. Bbs2-null mice have neurosensory deficits, a defect in social dominance, and retinopathy associated with mislocalization of rhodopsin. Proc Natl Acad Sci USA. 2004;101(47):16588–93.

    Article  PubMed  CAS  Google Scholar 

  60. Kim JC, Ou YY, Badano JL, Esmail MA, Leitch CC, Fiedrich E, Beales PL, Archibald JM, Katsanis N, Rattner JB, Leroux MR. MKKS/BBS6, a divergent chaperonin-like protein linked to the obesity disorder Bardet-Biedl syndrome, is a novel centrosomal component required for cytokinesis. J Cell Sci. 2005;118(Pt 5):1007–20.

    Article  PubMed  CAS  Google Scholar 

  61. Blacque OE, Reardon MJ, Li C, McCarthy J, Mahjoub MR, Ansley SJ, Badano JL, Mah AK, Beales PL, Davidson WS, Johnsen RC, Audeh M, Plasterk RH, Baillie DL, Katsanis N, Quarmby LM, Wicks SR, Leroux MR. Loss of C. elegans BBS-7 and BBS-8 protein function results in cilia defects and compromised intraflagellar transport. Genes Dev. 2004;18(13):1630–42.

    Article  PubMed  CAS  Google Scholar 

  62. Nishimura DY, Swiderski RE, Searby CC, Berg EM, Ferguson AL, Hennekam R, Merin S, Weleber RG, Biesecker LG, Stone EM, Sheffield VC. Comparative genomics and gene expression analysis identifies BBS9, a new Bardet-Biedl syndrome gene. Am J Hum Genet. 2005;77(6):1021–33.

    Article  PubMed  CAS  Google Scholar 

  63. Stoetzel C, Laurier V, Davis EE, Muller J, Rix S, Badano JL, Leitch CC, Salem N, Chouery E, Corbani S, Jalk N, Vicaire S, Sarda P, Hamel C, Lacombe D, Holder M, Odent S, Holder S, Brooks AS, Elcioglu NH, Silva ED, Rossillion B, Sigaudy S, de Ravel TJL, Alan Lewis R, Leheup B, Verloes A, Amati-Bonneau P, Megarbane A, Poch O, Bonneau D, Beales PL, Mandel J-L, Katsanis N, Dollfus H. BBS10 encodes a vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat Genet. 2006;38(5):521–24.

    Article  PubMed  CAS  Google Scholar 

  64. Chiang AP, Beck JS, Yen H-J, Tayeh MK, Scheetz TE, Swiderski RE, Nishimura DY, Braun TA, Kim K-YA, Huang J, Elbedour K, Carmi R, Slusarski DC, Casavant TL, Stone EM, Sheffield VC. Homozygosity mapping with SNP arrays identifies TRIM32, an E3 ubiquitin ligase, as a Bardetâ–Biedl syndrome gene (BBS11). Proc Natl Acad Sci USA. 2006;103(16):6287–92.

    Article  PubMed  CAS  Google Scholar 

  65. Stoetzel C, Muller J, Laurier V, Davis EE, Zaghloul NA, Vicaire S, Jacquelin C, Plewniak F, Leitch CC, Sarda P, Hamel C, de Ravel TJL, Lewis RA, Friederich E, Thibault C, Danse J-M, Verloes A, Bonneau D, Katsanis N, Poch O, Mandel J-L, Dollfus H. Identification of a Novel BBS Gene (BBS12) Highlights the Major Role of a Vertebrate-Specific Branch of Chaperonin-Related Proteins in Bardet-Biedl Syndrome. Am J Hum Genet. 2007;80(1):1–11.

    Article  PubMed  CAS  Google Scholar 

  66. Yoder BK, Tousson A, Millican L, Wu JH, Bugg CE Jr, Schafer JA, Balkovetz DF. Polaris, a protein disrupted in orpk mutant mice, is required for assembly of renal cilium. Am J Physiol Renal Physiol. 2002;282(3):F541–F52.

    PubMed  CAS  Google Scholar 

  67. Seo S, Guo DF, Bugge K, Morgan DA, Rahmouni K, Sheffield VC. Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet. 2009;18(7):1323–31.

    Article  PubMed  CAS  Google Scholar 

  68. Beales PL, Reid HA, Griffiths MH, Maher ER, Flinter FA, Woolf AS. Renal cancer and malformations in relatives of patients with Bardet-Biedl syndrome. Nephrol Dial Transplant. 2000;15(12):1977–85.

    Article  PubMed  CAS  Google Scholar 

  69. Park TJ, Haigo SL, Wallingford JB. Ciliogenesis defects in embryos lacking inturned or fuzzy function are associated with failure of planar cell polarity and Hedgehog signaling. Nat Genet. 2006;38(3):303–11.

    Article  PubMed  CAS  Google Scholar 

  70. Davenport JR, Watts AJ, Roper VC, Croyle MJ, van Groen T, Wyss JM, Nagy TR, Kesterson RA, Yoder BK. Disruption of intraflagellar transport in adult mice leads to obesity and slow-onset cystic kidney disease. Curr Biol. 2007;17(18):1586–94.

    Article  PubMed  CAS  Google Scholar 

  71. Alstrom C, Hallgren B, Nilsson L, Asander H. Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome (not hitherto described) distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree. Acta Psychiatr Neurol Scand. 1959;129:1–35.

    CAS  Google Scholar 

  72. Minton JA, Owen KR, Ricketts CJ, Crabtree N, Shaikh G, Ehtisham S, Porter JR, Carey C, Hodge D, Paisey R, Walker M, Barrett TG. Syndromic obesity and diabetes: changes in body composition with age and mutation analysis of ALMS1 in 12 United Kingdom kindreds with Alstrom syndrome. J Clin Endocrinol Metab. 2006;91(8):3110–16.

    Article  PubMed  CAS  Google Scholar 

  73. Marshall JD, Beck S, Maffei P, Naggert JK. Alstrom syndrome. Eur J Hum Genet. 2007;15(12):1193–202.

    Article  PubMed  CAS  Google Scholar 

  74. Marshall JD, Ludman MD, Shea SE, Salisbury SR, Willi SM, LaRoche RG, Nishina PM. Genealogy, natural history, and phenotype of Alstrom syndrome in a large Acadian kindred and three additional families. Am J Med Genet. 1997;73(2):150–61.

    Article  PubMed  CAS  Google Scholar 

  75. Hearn T, Renforth GL, Spalluto C, Hanley NA, Piper K, Brickwood S, White C, Connolly V, Taylor JFN, Russell-Eggitt I, Bonneau D, Walker M, Wilson DI. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alstrom syndrome. Nat Genet. 2002;31(1):79–83.

    PubMed  CAS  Google Scholar 

  76. Collin GB, Marshall JD, Ikeda A, So WV, Russell-Eggitt I, Maffei P, Beck S, Boerkoel CF, Sicolo N, Martin M, Nishina PM, Naggert JK. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom syndrome. Nat Genet. 2002;31(1):74–78.

    PubMed  CAS  Google Scholar 

  77. Hearn T, Spalluto C, Phillips VJ, Renforth GL, Copin N, Hanley NA, Wilson DI. Subcellular localization of ALMS1 supports involvement of centrosome and basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2 diabetes. Diabetes. 2005;54(5):1581–87.

    Article  PubMed  CAS  Google Scholar 

  78. Collin GB, Cyr E, Bronson R, Marshall JD, Gifford EJ, Hicks W, Murray SA, Zheng QY, Smith RS, Nishina PM, Naggert JK. Alms1-disrupted mice recapitulate human Alstrom syndrome. Hum Mol Genet. 2005;14(16):2323–33.

    Article  PubMed  CAS  Google Scholar 

  79. Marshall JD, Hinman EG, Collin GB, Beck S, Cerqueira R, Maffei P, Milan G, Zhang W, Wilson DI, Hearn T, Tavares P, Vettor R, Veronese C, Martin M, So WV, Nishina PM, Naggert JK. Spectrum of ALMS1 variants and evaluation of genotype-phenotype correlations in Alstrom syndrome. Hum Mutat. 2007;28(11):1114–23.

    Article  PubMed  CAS  Google Scholar 

  80. Bonora E. Relationship between regional fat distribution and insulin resistance. Int J Obes Relat Metab Disord. 2000;24:S32.

    Article  PubMed  CAS  Google Scholar 

  81. Nambu JR, Franks RG, Hu S, Crews ST. The single-minded gene of Drosophila is required for the expression of genes important for the development of CNS midline cells. Cell. 1990;63(1):63–75.

    Article  PubMed  CAS  Google Scholar 

  82. Holder JL Jr, Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet. 2000;9(1):101–8.

    Article  PubMed  CAS  Google Scholar 

  83. Michaud JL, Boucher F, Melnyk A, Gauthier F, Goshu E, Levy E, Mitchell GA, Himms-Hagen J, Fan CM. Sim1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet. 2001;10(14):1465–73.

    Article  PubMed  CAS  Google Scholar 

  84. Michaud JL, Rosenquist T, May NR, Fan CM. Development of neuroendocrine lineages requires the bHLH-PAS transcription factor SIM1. Genes Dev. 1998;12(20):3264–75.

    Article  PubMed  CAS  Google Scholar 

  85. Kublaoui BM, Holder JL Jr, Tolson KP, Gemelli T, Zinn AR. SIM1 overexpression partially rescues agouti yellow and diet-induced obesity by normalizing food intake. Endocrinology. 2006;147(10):4542–9.

    Article  PubMed  CAS  Google Scholar 

  86. Meyre D, Lecoeur C, Delplanque J, Francke S, Vatin V, Durand E, Weill J, Dina C, Froguel P. A genome-wide scan for childhood obesity-associated traits in French families shows significant linkage on chromosome 6q22.31-q23.2. Diabetes. 2004;53(3):803–11.

    Article  PubMed  CAS  Google Scholar 

  87. Duggirala R, Blangero J, Almasy L, Arya R, Dyer TD, Williams KL, Leach RJ, O’Connell P, Stern MP. A major locus for fasting insulin concentrations and insulin resistance on chromosome 6q with strong pleiotropic effects on obesity-related phenotypes in nondiabetic Mexican Americans. Am J Hum Genet. 2001;68(5):1149–64.

    Article  PubMed  CAS  Google Scholar 

  88. Hung C-CC, Luan J, Sims M, Keogh JM, Hall C, Wareham NJ, O’Rahilly S, Farooqi IS. Studies of the SIM1 gene in relation to human obesity and obesity-related traits. Int J Obes. 2006;31(3):429–34.

    Article  CAS  Google Scholar 

  89. Gray J, Yeo GS, Cox JJ, Morton J, Adlam AL, Keogh JM, Yanovski JA, El Gharbawy A, Han JC, Tung YC, Hodges JR, Raymond FL, O’Rahilly S, Farooqi IS. Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes. 2006;55(12):3366–71.

    Article  PubMed  CAS  Google Scholar 

  90. Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, O’Rahilly S, Farooqi IS. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci. 2004;7(11):1187–9.

    Article  PubMed  CAS  Google Scholar 

  91. Han JC, Liu QR, Jones M, Levinn RL, Menzie CM, Jefferson-George KS, Adler-Wailes DC, Sanford EL, Lacbawan FL, Uhl GR, Rennert OM, Yanovski JA. Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med. 2008;359(9):918–27.

    Article  PubMed  CAS  Google Scholar 

  92. Tapia-Arancibia L, Rage F, Givalois L, Arancibia S. Physiology of BDNF: focus on hypothalamic function. Front Neuroendocrinol. 2004;25(2):77–107.

    Article  PubMed  CAS  Google Scholar 

  93. Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, Tecott LH, Reichardt LF. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003;6(7):736–42.

    Article  PubMed  CAS  Google Scholar 

  94. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 2000;19(6):1290–300.

    Article  PubMed  CAS  Google Scholar 

  95. Pelleymounter MA, Cullen MJ, Wellman CL. Characteristics of BDNF-induced weight loss. Exp Neurol. 1995;131(2):229–38.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by NIH grant 1K23-RR-021979 to AMH. I thank Dr. Seth Marks for his helpful editorial comments.

Author information

Authors and Affiliations

  1. Division of Pediatric Endocrinology, Department of Pediatrics, University of Alberta, T6G 2J3, Edmonton, AB, Canada

    Andrea M. Haqq

Authors
  1. Andrea M. Haqq
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatric Endocrinology, and Diabetes, Duke University, DUMC 3080, Durham, 27710, North Carolina, USA

    Michael Freemark

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Haqq, A.M. (2010). Syndromic Obesity. In: Freemark, M. (eds) Pediatric Obesity. Contemporary Endocrinology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-60327-874-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-874-4_4

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-60327-873-7

  • Online ISBN: 978-1-60327-874-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation